Objective-To determine the contribution of dexamethasone to the efficacy of the 5-hydroxytryptamine antagonist ondansetron in control of cisplatin induced nausea and vomiting.
Introduction
Cisplatin is one of the most emetogenic chemotherapeutic agents and treatment with high doses produces acute nausea and vomiting in all patients within 24 hours unless antiemetic drugs are used.' Partial control of emesis can be obtained, but none of the widely used antiemetic drugs is fully effective. Furthermore, high doses of antiemetic drugs such as metoclopramide, which act by antagonism at central dopamine receptors, may produce extrapyramidal effects in up to 10% of patients. 2 Ondansetron is a selective 5-hydroxytryptamine receptor antagonist which is devoid of any effects on dopamine receptors.' It can usually prevent emesis and nausea produced by chemotherapy4 or radiotherapy.'
In controlled studies ondansetron has been shown to be superior to high dose metoclopramide in preventing cisplatin induced emesis and nausea. 6 However, emesis and nausea in about 30% of patients remains inadequately controlled by ondansetron. Dexamethasone is known to have antiemetic properties, especially when used in high dosage.7 Its mechanism of action is unknown, but we have shown that dexamethasone can enhance the efficacy of metoclopramide in treating cisplatin induced emesis. ' In a recent study in ferrets treated with cyclophosphamide considerable enhancement of the antiemetic effect of a suboptimal dose of ondansetron was shown when it was combined with dexamethasone.' Recent pilot studies have shown an increased clinical effectiveness of ondansetron when given with dexamethasone for preventing emesis in patients who were refractory to ondansetron treatment.'01
We compared the clinical efficacy and safety of ondansetron alone and in combination with dexamethasone in the prophylaxis of nausea and vomiting in the first 24 hours after cancer chemotherapy with cisplatin. We also studied the efficacy and safety of ondansetron alone in the prophylaxis of delayed nausea and vomiting (on days 2-6) induced by cisplatin.
Patients and methods
The study comprised 100 patients (53 men and 47 women) with various malignancies and a median age of 51 years (range years) who were receiving their first course of cancer chemotherapy with cisplatin 100 mg/m2 over one hour and scheduled to receive at least two courses. It was conducted at one centre in the United Kingdom and one in Germany and was approved by their respective local ethics committees. Consent was obtained from each patient before participation in the study. Patients were considered ineligible if they were clinically jaundiced, had active peptic ulceration, had vomited in the 24 hours before chemotherapy or had received antiemetics during this period, or were receiving concurrent benzodiazepines (except for night sedation).
The study had a randomised, double blind, crossover design. Randomisation was computer generated by using a patient allocation for clinical trials program. All patients were inpatients for at least 24 hours. According to the randomisation code, patients first received either intravenous dexamethasone (20 mg) or physiological saline 30 minutes before receiving cisplatin. The injections were blinded by the hospital pharmacist. This was followed by a slow intravenous injection of any patient totally failed to respond-that is, experienced more than five episodes of vomits or retches, or both, in the 24 hours after starting to receive cisplatin -then he or she could be given an antiemetic as a rescue medication. A total of 100 patients were estimated to give the study a power of 0-8 at the 5% significance level to discriminate between overall success rates (0-2 emetic episodes) of 65% with ondansetron plus dexamethasone and 45% with ondansetron alone. Sixty patients were recruited from the British centre and 40 from the German centre. The analyses included tests for interaction between treatment and centre. The primary response to antiemetic treatment was based on the percentage of patients who experienced complete or major (0-2 emetic episodes) control of emesis over the first 24 hours. An emetic episode was defined as any vomit productive of liquid or 1-5 retches within a five minute period. The time to first emetic episode during the first 24 hours was calculated from the records of vomits and retches. If the number of emetic episodes was 0, the time to first emetic episode was censored at 24 hours and an arbitrary value of 25 hours used in the analysis of ranked times. Data were analysed on the basis ofintention to treat for all patients completing the first two courses and for patients considered fully evaluable by adequate protocol compliance over those courses.
The number of emetic episodes was comparedbetween treatments by using non-parametric methods for a crossover design based on Wilcoxon rank sum tests.2 The response to treatment was graded a success if the patient experienced 0-2 emetic episodes and a failure otherwise. These binary response data were analysed according to methods appropriate to the crossover design.'3 14 The patient preference data were analysed by Prescott's method. ' BMJ VOLUME 303 patients respectively. Two major adverse events were thought probably to be related to antiemetic treatment. One patient had severe constipation after the first course and required readmission to the hospital and withdrawal from the alone (69% v 56%). The differences in antiemetic efficacy were significant for analysis both by intention to treat (p=0-012) and of the fully evaluable (p=0 035) patient population. Although there was no significant evidence of any treatment and centre interactions, examination of the data on efficacy of treatment and treatment preference showed that the advantage of dexamethasone was more apparent in the British centre.
Our observations support, although do not match, the data of Roila et al. '7 In their study complete control of cisplatin induced emesis was achieved in 91% of patients treated with a combination ofondansetron and dexamethasone compared with 64% given ondansetron alone. Also, in agreement with this study, acute nausea induced by cisplatin was controlled more effectively by ondansetron when it was given with dexamethasone. In all, 80% of patients receiving the combination treatment graded their nausea within 24 hours as none or mild compared with 68% of patients treated with ondansetron alone. Double blind crossover studies can be useful in providing information such as a patient's preference for treatment. In this study patient preference was assessed after the completion of both treatment courses. Of the 53 patients indicating a preference, 38 (72%) preferred the combination treatment compared with 15 
